



**Supplemental figure S1.** Incidences and landmark choice of the three pazopanib-induced toxicities. **(A)** Number of patients with cardiotoxicity related adverse events while on treatment with pazopanib. **(B)** Number of patients with proteinuria while on treatment with pazopanib. **(C)** Number of patients with hypothyroidism (TSH cut-off point 4mU/L) while on treatment with pazopanib.



**Supplemental figure S2.** Kaplan-Meier curves showing the progression-free survival **(A)** and overall survival **(B)** of patients receiving pazopanib with and without cardiotoxicity of any grade.



**Supplemental figure S3.** Kaplan-Meier curves showing the progression-free survival **(A)** and overall survival **(B)** of patients receiving pazopanib with and without persistent proteinuria.

